Finance

Lists
Why is 300562 down 3,25%?
Dive Deeper
300562:SHE
Guangdong Transtek Medicl Elctrncs CoLtd
CN¥13,41
-3,25%
(-0,45) 1D
15 Okt., 15:04:40 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 300562...
Open
CN¥13,50
High
CN¥13,80
Low
CN¥13,35
Mkt. cap
3,15 mjd
Avg. vol.
16,71 m
Volume
8,70 m
Dividend
1,94%
Quarterly dividend
CN¥0,06
Ex-dividend date
15 Okt. 2026
P/E ratio
29,36
52-wk high
CN¥19,54
52-wk low
CN¥11,32
EPS
CN¥0,46
Shares outstanding
218,93 m
No. of employees
1 k
Open
CN¥13,50
High
CN¥13,80
Low
CN¥13,35
Mkt. cap
3,15 mjd
Avg. vol.
16,71 m
Volume
8,70 m
Dividend
1,94%
Quarterly dividend
CN¥0,06
Ex-dividend date
15 Okt. 2026
P/E ratio
29,36
52-wk high
CN¥19,54
52-wk low
CN¥11,32
EPS
CN¥0,46
Shares outstanding
218,93 m
No. of employees
1 k
News stories
From web sources and news partners
Profile
Transtek Medical, commonly known as Lifesense, fully referred to as Guangdong Transtek Medical Electronics Co., Ltd., is a Chinese wearable device maker that also focuses on the field of mobile health. The company was founded by Weichao Pan in 2002, with its main products being home medical and health electronics, such as scales, smart bracelets and blood pressure monitors. According to IDC, the company shipped one million units of wearables in the second quarter of 2016, ranking fifth in the global wearable devices market, coming in behind Fitbit, Apple and Garmin. Transtek's IPO application was approved by the CSRC in October 2016. On November 16, it landed on the Shenzhen Stock Exchange with the ticker symbol "300562.SZ". Wikipedia
About Guangdong Transtek Medicl Elctrncs CoLtd
CEO-
Employees1,09 k
Founded18 Jul. 2002
Headquarters-
SectorMedical device
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
235,76 m
229,08 m
283,74 m
250,69 m
Cost of goods sold
149,14 m
152,94 m
176,58 m
166,11 m
Cost of revenue
149,14 m
152,94 m
176,58 m
166,11 m
Research and development expenses
20,36 m
24,79 m
26,69 m
23,33 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
41,57 m
26,45 m
41,12 m
21,85 m
Operating expense
58,96 m
52,61 m
71,19 m
48,25 m
Total operating expenses
208,10 m
205,55 m
247,78 m
214,35 m
Operating income
27,66 m
23,53 m
35,96 m
36,34 m
Other non operating income
-3,39 m
2,22 m
-4,58 m
3,96 m
EBT including unusual items
23,63 m
16,59 m
32,82 m
31,28 m
EBT excluding unusual items
25,70 m
24,73 m
31,68 m
34,21 m
Income tax expense
118,51 k
1,08 m
931,10 k
3,84 m
Effective tax rate
0,50%
6,54%
2,84%
12,27%
Other operating expenses
-1,92 m
3,87 m
1,19 m
2,80 m
Net income
23,39 m
16,32 m
32,07 m
27,96 m
Net profit margin
9,92%
7,12%
11,30%
11,15%
Earnings per share
-
-
-
-
Interest and investment income
3,39 m
2,85 m
330,33 k
3,10 m
Interest expense
-1,40 m
-
-37,02 k
-57,71 k
Net interest expenses
1,99 m
2,85 m
293,32 k
3,05 m
Depreciation and amortization charges
-
-
-
-
EBITDA
32,45 m
28,29 m
40,73 m
41,00 m
Gain or loss from assets sale
-150,13 k
26,11 k
-
-1,36 m
AI content may include mistakes. Learn more
Google-programme